Generic drugs are in a race—and the rules of the track are changing.
If you’ve ever wondered why some generic launches feel like clockwork while others get delayed for years, the answer is often buried in the fine print of the Hatch-Waxman Act. In a re…

Biopharma’s “patent cliff” isn’t just a legal event—it’s a commercial deadline.
If you sell into European healthcare systems, you already know the headlines: patents expire, generics and biosimilars arrive, and pricing pressure follows. But the real …

Biopharma talent is moving—fast—and the “where” is showing up in the patent wars.
If you’ve been watching biosimilar litigation as a niche sideshow, you’re missing the signal. The latest wave of biosimilar patent disputes isn’t just about molecules and…

Specialty pharmacy contracts aren’t just “commercial.” They’re a patent-timing strategy.
In biopharma, the clock doesn’t start when a drug launches—it starts when the patent wall begins to thin. Yet many business development teams still approach spec…

Apotex has filed for approval of its ruxolitinib drug with the US Food and Drug Administration (FDA) [1]. According to the… https://www.Drugchatter.com/chat/11297/can-you-confirm-apotex’s-ruxolitinib-us-filing-date/

Apotex has filed for approval of its ruxolitinib drug with the US Food and Drug Administration (FDA) [1]. According to the… https://www.Drugchatter.com/chat/11297/can-you-confirm-apotex’s-ruxolitinib-us-filing-date/

Apotex has filed for approval of its ruxolitinib drug with the US Food and Drug Administration (FDA) [1]. According to the… https://www.Drugchatter.com/chat/11297/can-you-confirm-apotex’s-ruxolitinib-us-filing-date/

Apotex has filed for approval of its ruxolitinib drug with the US Food and Drug Administration (FDA) [1]. According to the… https://www.Drugchatter.com/chat/11297/can-you-confirm-apotex’s-ruxolitinib-us-filing-date/

Apotex has filed for approval of its ruxolitinib drug with the US Food and Drug Administration (FDA) [1]. According to the… https://www.Drugchatter.com/chat/11297/can-you-confirm-apotex’s-ruxolitinib-us-filing-date/